One year of low-dose rapamycin in healthy adults — what actually happened.
TL;DR: The PEARL trial — the largest community-based rapamycin longevity study in healthy adults — found that low-dose rapamycin was generally safe and well tolerated over one year. Some healthspan markers moved in promising directions, but the study did not measure lifespan, and rapamycin remains unproven as an anti-ageing treatment in humans.
PEARL stands for Participatory Evaluation of Aging With Rapamycin for Longevity. It is a prospective, randomised, double-blind, placebo-controlled trial of low-dose rapamycin in healthy adults, run largely through community participation and telemedicine.
The trial was designed to answer a practical question: can the lifespan-extending effects seen in mice on rapamycin be safely explored in otherwise healthy humans, at least in terms of healthspan markers?
The published one-year results reported:
The authors were careful to frame the findings as promising but preliminary. The PEARL trial is best understood as a safety and feasibility signal, not a definitive longevity result.
mTOR (mechanistic target of rapamycin) is a cellular nutrient sensor. When nutrients are abundant, mTOR pushes cells toward growth and protein synthesis. When nutrients are scarce, mTOR activity drops and cells shift toward maintenance, recycling and autophagy.
Lifespan studies in yeast, worms, flies and mice consistently show that reducing mTOR signalling extends life. Rapamycin is the best-known mTOR inhibitor and has extended lifespan in multiple mouse strains even when started in middle age.
The challenge for humans is that mTOR also supports wound healing, immune response and muscle growth. Blunt suppression can backfire. That is why dosing, schedule and individual health status matter enormously.
PEARL is an important step because it moves rapamycin discussion from mouse studies into controlled human data. But it is not a green light for self-experimentation. In the UK, rapamycin is a prescription-only medicine used in transplant patients and some cancer regimens. Taking it "off-label" for longevity requires specialist oversight, regular blood monitoring and a clear risk-benefit discussion.
There are no affiliate product links for rapamycin. Do not purchase prescription medicines from unregulated online sellers.
These sources are referenced inline throughout the article and listed below for full transparency.
"Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results." The primary one-year report from the PEARL community-based rapamycin longevity trial.
View DOI"Rapamycin fed late in life extends lifespan in genetically heterogeneous mice." Landmark study showing lifespan extension even when rapamycin is started in middle age.
View DOI"Rapamycin improves immune function in old mice by reducing senescence and inflammation." Key mechanistic link between mTOR inhibition and immune ageing.
View DOI"mTOR inhibition improves immune function in the elderly." Early human evidence that low-dose mTOR inhibitors can boost vaccine response in older adults.
View DOIPEARL (Participatory Evaluation of Aging With Rapamycin for Longevity) was a prospective, double-blind, placebo-controlled trial that gave low-dose rapamycin to healthy adults for one year and measured safety and healthspan markers.
No. PEARL was not designed to measure lifespan. It measured safety, tolerability and healthspan biomarkers over one year. No lifespan data are available.
Rapamycin is a prescription immunosuppressant with real risks, including mouth ulcers, lipid changes, impaired wound healing and immune suppression. The PEARL trial reported that the low-dose regimen was generally tolerated, but it is not approved as an anti-ageing treatment and should not be taken without medical supervision.
Rapamycin inhibits mTOR, a nutrient-sensing pathway that coordinates cell growth, protein synthesis and autophagy. In animal studies, mTOR inhibition extends lifespan in yeast, worms, flies and mice. Human translation is unproven.